Skip to content

Sermorelin Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

Individual responses vary based on age, baseline GH and IGF-1 levels, body composition, diet, and exercise habits. The following timelines reflect patterns reported in clinical studies and prescriber experience:

Weeks 1 to 4:

  • Improved sleep quality, including deeper sleep and more vivid dreams, is often the earliest reported benefit
  • Mild increases in energy and daytime alertness
  • Some users report improved mood and sense of wellbeing

Weeks 4 to 8:

  • Measurable increases in serum IGF-1 levels (typically detectable by week 4 to 6)
  • Improved recovery from exercise, with reduced soreness and faster return to baseline
  • Early improvements in skin hydration, thickness, and elasticity

Months 2 to 6:

  • Progressive improvements in body composition: increased lean mass (one study demonstrated a significant 1.26 kg increase in men) and reductions in body fat, particularly visceral adipose tissue
  • Strength and exercise tolerance improvements
  • Enhanced collagen production visible in skin quality, hair, and nail growth
  • Continued improvement in sleep architecture
  • One study in older adults showed a 35% increase in IGF-1 levels with 6 months of bedtime sermorelin injections

Maximum benefits are generally observed at the 3 to 6 month mark with consistent use. Clinicians typically reassess IGF-1 levels and clinical response at 3-month intervals to adjust dosing.

Frequently Asked Questions

Both are GHRH analogs, but they differ significantly in half-life. Sermorelin has a half-life of about 11 to 12 minutes and requires daily injections. CJC-1295 with DAC has a half-life of 5 to 8 days, requiring only weekly dosing. CJC-1295 produces more sustained GH elevation, while sermorelin more closely mimics the body's natural pulsatile GH release pattern.

The most frequently reported side effects are mild injection site reactions (redness, swelling, itching), transient facial flushing lasting a few minutes, and headache, particularly during the first 1 to 2 weeks of therapy. Most side effects resolve as the body adjusts to treatment.

Improved sleep quality is often the first noticeable effect, typically within 1 to 2 weeks. Measurable changes in IGF-1 levels appear within 4 to 6 weeks. Body composition improvements, including fat loss and increased lean mass, generally require 3 to 6 months of consistent use.

Most anti-aging protocols use 200 to 300 mcg administered subcutaneously at bedtime, 5 nights per week. Dosing is individualized based on age, IGF-1 levels, and clinical response. A healthcare provider should determine the appropriate dose and monitor progress.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
  2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
  3. Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
  4. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
  5. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159.
  6. FDA. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78(42):14219-14220.
  7. World Anti-Doping Agency. The 2025 Prohibited List International Standard.
  8. Sermorelin Acetate. RxList Drug Database.
  9. PubChem. Sermorelin (CID 16132413).
  10. Sermorelin. DrugBank (DB00010).

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”